Related by context. All words. (Click for frequent words.) 64 pharmacogenomic translational research 64 midstage clinical 64 oral picoplatin 64 alvespimycin 64 AAG geldanamycin analog 63 Panzem NCD 63 recombinant PSMA vaccine 63 generation purine nucleoside 63 including eniluracil ADH 62 hypoxia activated prodrug 62 TELINTRA R 62 MVA MUC1 IL2 62 MEND CABG II 62 Phase Ib II 62 MAGE A3 ASCI 62 Bayer HealthCare Onyx Pharmaceuticals 62 PANVAC VF 62 hyaluronidase enzyme 61 ALN VSP Phase 61 Panzem R NCD 61 Fx #A 61 trastuzumab DM1 T DM1 61 CA9 SCAN 61 PI3K/Akt pathway inhibitor 61 OvaRex R 61 PSMA ADC 61 Phase III ADT 61 Rigel R# 61 CB2 selective receptor agonist 61 rALLy clinical trial 61 tramiprosate Alzhemed TM 61 Ostabolin C TM 61 Archexin 61 vidofludimus 61 EGS# 61 opioid naive 61 phase IIa clinical 61 Hematide ™ peginesatide 60 seliciclib CYC# 60 Angiocept 60 CEL SCI Phase III 60 RESTORE CLI trial 60 initiate Phase 2b 60 SYN# 60 intranasal insulin product 60 solid tumors ZYBRESTAT 60 zileuton injection 60 Phase #b/#a clinical 60 Azedra TM 60 Cloretazine ® 60 novel therapeutic antibodies 60 IMC #B 60 Phase IIIb clinical 60 CYT# potent vascular disrupting 59 imetelstat GRN#L 59 phase IIb 59 next generation URAT1 59 Matrix Phase 2b 59 APEX PD 59 drug figitumumab 59 commercialize CorMedix drug 59 Enzastaurin 59 tezampanel NGX# 59 THR beta agonist 59 MKC# MT 59 pivotal bioequivalence 59 confirmatory pivotal 59 Recurrent Glioblastoma 59 SUTENT ® 59 Xcellerated T Cells 59 E1 INT TM 59 generation URAT1 inhibitor 59 TBC# 59 ONCONASE R 59 Initiate Phase 59 Romidepsin 59 initiated Phase Ib 59 PNP inhibitor 59 davalintide 59 Hematide ™ 59 multicenter Phase II 59 NOX E# 59 Sudhir Agrawal D.Phil 59 Insulin PH# 59 candidate REP# 59 Zemplar Capsules 59 triggers apoptosis programmed 59 receptor tyrosine kinase inhibitor 59 albiglutide 59 orally administered inhibitor 59 Zybrestat 59 DXL# 59 CCR9 antagonist 59 iii GTx 59 EVIZON TM squalamine lactate 59 E2F Decoy 59 Plicera 59 Deforolimus 59 Syncria albiglutide 59 visit http:/www.clinicaltrials.gov/ 59 intravenous methylnaltrexone 59 Corlux 59 AKT inhibitor 58 MediGene focuses 58 DEB# 58 ongoing Phase 1b 58 Investigational Oral 58 oral prodrug 58 Tarvacin Anti Cancer 58 EmbraceAC 58 galiximab 58 phase IIa 58 IMA# 58 evaluating Prochymal 58 non nucleoside inhibitor 58 LHRH receptor positive 58 radiation sensitizer 58 Second Pivotal Phase 58 Phase 1a clinical 58 BRIM2 58 PDE4 inhibitor 58 Zenvia ™ 58 Phase Ib study 58 Trofex 58 phase IIb clinical 58 Phase 2a clinical trials 58 Phase IIb trials 58 pafuramidine maleate 58 resectable pancreatic cancer 58 GVAX ® 58 BRIM3 58 selectin antagonist 58 Exherin TM 58 Phase Ib IIa 58 ADCIRCA 58 Annamycin 58 sapacitabine CYC# 58 AdhTAP 58 humanised monoclonal antibody 58 TKM PLK1 58 Prodarsan R 58 gemcitabine Gemzar ® 58 generation PNP inhibitor 58 overactive bladder AA# 58 Completes Patient Enrollment 58 TASKi2 58 oral ridaforolimus 58 MKC# 58 TOCOSOL Camptothecin 58 VIAject 58 orally inhaled migraine 58 LymphoStat B belimumab 58 multicenter Phase III 58 Phase III confirmatory 57 aflibercept VEGF Trap 57 targeted radiotherapeutic 57 humanized therapeutic 57 rotary VAD 57 PresbyLens ® 57 initiate multicenter 57 initiate Phase Ib 57 number NCT# ClinicalTrials.gov 57 tolevamer 57 Initiates Enrollment 57 signal detection CTSD 57 Solazed 57 sulfonylurea glimepiride 57 Phase IIb clinical 57 phase Ib 57 Combination REOLYSIN R 57 paclitaxel Taxol R 57 budesonide MMX Phase III 57 PRECISE Trial 57 SILENOR 57 metaglidasen 57 Phase 2b MATRIX 57 Safinamide 57 MCSP respectively 57 kidney urologic 57 Phase IIb III 57 OvaRex ® MAb 57 DEEP AF 57 brivanib 57 KRN# 57 leading oral taxane 57 class mGluR5 inhibitor 57 polycythemia vera essential thrombocythemia 57 rALLy 57 lumiliximab 57 biliary tract cancer 57 telomerase inhibitor drug 57 Cloretazine 57 genomic biomarker 57 IMPACT DCM 57 IMPDH inhibitor 57 initiate Phase 1b 57 NPC 1C 57 GLP toxicology studies 57 noninvasive outpatient 57 BrachySil TM 57 Aplidin 57 acute peripheral arterial 57 IND submission 57 Pyridorin 57 TransVax 57 LymphoStat B TM 57 Phase Ib 57 Phase lll 57 Cloretazine R 57 SinuNase ™ 57 Anavex #-# 57 Tasigna prolongs 57 GALNS 57 ZOLINZA 57 oral talactoferrin 57 cromolyn sodium 57 RhuDex TM 57 XL# SAR# 57 CRMD# 57 rhIGF-I/rhIGFBP-3 57 PRIMO CABG 57 evaluating satraplatin 57 fusion enhancers 57 IIa clinical 57 Initiates Phase II 57 R#/MEM # 57 phase IIb trial 57 metastatic colorectal 57 dexanabinol 57 Factor VIIa 57 Randomized Phase II 57 PEARL SC 57 randomized controlled multicenter 57 GRN# 57 TASKi3 57 HQK 57 adecatumumab MT# 57 confirmatory clinical 57 preclinical pharmacology 57 metastatic colorectal carcinoma 57 Lixivaptan 57 granted Ortec 57 antiangiogenic agent 57 intravenous RSD# 57 Phase IIb clinical trials 57 BRAF inhibitor 57 EXPLORE Xa 57 Prodarsan ® 57 semi synthetic lipoglycopeptide 56 management biostatistical analysis 56 ThermoDox ® clinical 56 FOLFOX6 chemotherapy regimen 56 Pivotal Phase III 56 TLK# 56 HuMax TAC 56 incyclinide 56 GENZ # 56 therapeutic monoclonal antibody 56 aurora kinase 56 ACAPODENE TM 56 BLA filing 56 Genz # 56 Triapine R 56 Alzhemed TM 56 ficlatuzumab 56 clinical trials Archexin 56 Phase 1b clinical trials 56 PF # [002] 56 preclinical studies Vion 56 oxypurinol 56 TRIOLEX HE# APOPTONE HE# 56 refractory metastatic 56 FavId 56 5 fluorouracil leucovorin 56 cathepsin K inhibitor 56 brentuximab vedotin SGN 56 sunitinib Sutent 56 midstage clinical trials 56 isatoribine 56 solanezumab 56 registrational Phase 56 Liposomal Grb 2 56 forodesine 56 Pimavanserin 56 catheter occlusion 56 dyslipidemia hypertension diabetes 56 Neuvenge 56 subcutaneous PRO 56 Trofex TM 56 oral ghrelin agonist 56 follicular Non Hodgkin 56 GERD migraine headaches 56 ACCEDE 56 CINQUIL 56 PrevOnco ™ 56 IMC A# 56 R sorafenib tablets 56 vernakalant hydrochloride 56 CBLC# 56 transmucosal delivery system 56 miconazole Lauriad 56 Tectin TM 56 PEG SN# 56 Xcytrin R 56 IAP inhibitor 56 beta 1a 56 SAR# [004] 56 REVIVE Diabetes 56 Proellex TM 56 basal insulin analogue 56 evaluating picoplatin 56 QNEXA ® 56 Phase #b/#a trial 56 Luramist TM 56 CHAMPION PCI 56 Daclizumab 56 EMPOWER ™ 56 L BLP# 56 Refractory Angina 56 VNP#M 56 OncoVex 56 INS# [001] 56 phase IIIb 56 Phase III Pivotal 56 reduce serum phosphate 56 Targretin capsules 56 Fodosine 56 SUCCEED trial 56 Trastuzumab DM1 56 cannabinor 56 Aurora kinase inhibitor 56 blinded randomized placebo controlled 56 Phase III multicenter 56 Pharmos pipeline 56 tanespimycin 56 Specifid 56 epigenetic therapies 56 atacicept 56 TRIST 56 IL# PE#QQR 56 TNFerade TM 56 Phase 1b trial 56 Capesaris 56 MGd 56 ELACYT 56 Kahalalide F 56 acute mania 56 subcutaneous formulation 56 Temsirolimus 56 Cand5 56 ® bortezomib 56 ADVEXIN therapy 56 GLPG# 56 Crofelemer budesonide foam 56 evaluating Actimmune 56 fosbretabulin 56 MIST II 56 phase IIb study 56 preclinical pharmacokinetic 56 subcutaneous SC 56 systemically administered 56 NP2 Enkephalin 56 ENGAGE AF TIMI 56 Vitaxin 56 anti botulism antibody 56 IMiDs R 56 2A receptor agonist 56 novel emulsion formulation 56 GMX# 56 Pegloticase 56 RECORD1 56 IND enabling 56 Androxal TM 56 AS# amonafide L malate 56 preclinical efficacy 55 Spiegelmer ® 55 Omacetaxine 55 TMC# [002] 55 OMP #R# 55 Aflibercept 55 evaluating tivozanib 55 Inhaled nitric oxide 55 Tyrima 55 Proxinium TM 55 TKM ApoB 55 ARIKACE ™ 55 velafermin 55 Albuferon albinterferon alfa 2b 55 generation rotary VAD 55 CD# CEA 55 bardoxolone 55 thalidomide Thalomid 55 elacytarabine 55 Initiate Clinical Trial 55 TRO# 55 QuadraSphere 55 Initiates Clinical 55 MAXY VII 55 Virulizin ® 55 Allovectin 7 55 PEGPH# 55 refractory colorectal cancer 55 Nasulin ™ 55 drug NP2 Enkephalin 55 EVIZON TM 55 LEAPS H#N# 55 PROVENGE ® 55 azilsartan medoxomil 55 omacetaxine mepesuccinate 55 ENABLE Phase 2 55 Reports Preclinical Data 55 Presents Preclinical 55 M# rationally 55 Chemophase 55 Phase Ib clinical 55 pharmacokinetic PK study 55 dermatology biopharmaceutical company 55 compound INCB# 55 Zemiva TM 55 Posiphen TM 55 HDL Selective Delipidation 55 diabetes irritable bowel 55 Initiates Clinical Trial 55 Hedgehog inhibitor 55 OvaRex 55 Phase 2b clinical 55 dose intramuscular 55 Meets Primary Endpoint 55 mertansine 55 Panzem ® 55 Urocortin 2 55 apoptosis inducer 55 deforolimus 55 Begins Dosing 55 ALK inhibitors 55 CG# [003] 55 treating neuropathic pain 55 CRLX# 55 TransVax tm 55 lorcaserin Phase 55 isoform selective 55 coronary stent merged 55 ANCHOR trial 55 canagliflozin 55 HCV polymerase 55 pertuzumab 55 dimebon latrepirdine 55 Omnitarg 55 unique alkylating agent 55 PEGylated interferon 55 Trandolapril 55 Albuferon Phase 55 GRNVAC1 55 midstage trials 55 PS# DARA 55 Phase 2b Clinical Trial 55 KRYSTEXXA TM pegloticase 55 acyclovir Lauriad R 55 intranasal formulation 55 targeting miR 55 AERx ® 55 Vidaza ® 55 randomized Phase 2b 55 3 registrational trial 55 implantable centrifugal rotary 55 evaluating T DM1 55 HEPLISAV TM hepatitis B 55 histamine dihydrochloride 55 Panzem 55 chronic thromboembolic pulmonary 55 Onconase 55 eniluracil 55 samalizumab 55 Initiates Phase 2b 55 Phase #b/#a 55 mediated inhibition 55 AQ4N 55 previously untreated follicular 55 topical antifungal product 55 GSK# [002] 55 Evoltra ® 55 Smac mimetics 55 Provacel 55 PRECISE trial 55 indolent follicular non 55 Tesmilifene 55 liposomal doxorubicin 55 sargramostim 55 aplindore 55 development peramivir neuraminidase 55 ruxolitinib 55 MEND CABG 55 transgenically produced product 55 Eniluracil 55 ALB # 55 demonstrated antitumor activity 55 bortezomib Velcade 55 http:/www.vivus.com 55 treat chronic sinusitis 55 OAB overactive bladder 55 ospemifene 55 indibulin 55 Phase III TRIST 55 chemosensitizer 55 oral methylnaltrexone 55 Memryte 55 anticancer compound 55 pretransplant 55 sulfonylurea metformin 55 recurrent glioblastoma multiforme 55 Begins Clinical Trial 55 NSABP C 55 gamma secretase inhibitor 55 Dose Ranging Study 55 phase Ib clinical 55 antiangiogenic therapy 55 Achieves Primary Endpoint 55 Salix Pharmaceuticals Announces 55 JAK inhibitor 55 AZX# Phase 55 relapsed MM 55 lorvotuzumab mertansine 55 Urocidin 55 huC# DM4 55 initiate Phase IIb 55 Preclinical studies suggest 55 PROSTVAC VF 55 Budesonide foam crofelemer 55 hoFH 55 aurora kinase inhibitor 55 cetuximab Erbitux 55 HuMax EGFr 55 APEX AMI 55 PTK# 55 phase III isavuconazole 55 delivers fluocinolone acetonide FA 54 deCODE ProstateCancer TM 54 octreotide implant 54 GENASIS clinical 54 Allovectin 7 ® 54 JAK#/JAK# inhibitor CYT# 54 Advaxis Phase 54 candidate deforolimus 54 GVAX R 54 product platforms GVAX 54 oral sapacitabine 54 human microdosing 54 maximally tolerated dose 54 Intravail R 54 FUSILEV enhances 54 PDE# inhibitors 54 Inc. Nasdaq TNGN 54 riociguat 54 unresectable tumors 54 HRPC ovarian cancer 54 Phase IIB 54 preclinically 54 anti PlGF 54 clevidipine 54 edifoligide 54 humanised antibody 54 cediranib 54 Raf kinase inhibitor 54 IIb clinical trial 54 Cloretazine R VNP#M 54 Initiated Phase 54 opioid induced bowel dysfunction 54 lymphomas leukemias 54 Q#IR 54 sitaxsentan 54 phase IIb III 54 estrogen receptor beta agonist 54 vitro ADME 54 varespladib 54 EOquin 54 Mipomersen 54 bavituximab monotherapy trial 54 randomized Phase IIb 54 Troxatyl 54 pediatric pontine glioma 54 novel immunotherapies 54 GED aPC 54 Phase 2b RESTORE CLI 54 LCP Tacro 54 Talotrexin 54 potent antiproliferative 54 Aeolus Pharmaceuticals Announces 54 DAC HYP 54 sterile lidocaine patch 54 R lenalidomide 54 volociximab 54 Poly ICLC 54 Successfully Completes Phase 54 Initiates Phase III 54 taxane chemotherapy administered 54 deCODE AF TM 54 StemEx R 54 vaccine GMK 54 Squalamine 54 retaspimycin 54 reslizumab 54 Phase 2b kidney transplant 54 injectable investigational 54 TransMID 54 Prednisone Against Refractory 54 evaluating bavituximab 54 Empatic ™ 54 Viprinex TM 54 VITAL Trial 54 intravenous picoplatin include 54 IL-#/# 54 lomitapide 54 Accelerating apoptosis may 54 retinal vein occlusion induced 54 visilizumab 54 Phase IIb randomized 54 placebo controlled dose escalation 54 oncolytic virus therapies 54 dose escalation clinical 54 palifosfamide 54 CYT# vascular disrupting 54 evaluating satraplatin plus 54 progressive metastatic prostate 54 undergoing hematopoietic stem 54 lintuzumab 54 Cogane 54 XOMA 3AB 54 lenalidomide Revlimid R 54 lung pancreatic 54 sorafenib Nexavar 54 romazarit 54 Zavesca r 54 approved incretin mimetic 54 occlusion PAO 54 neratinib 54 induced tumor regression 54 SILENOR TM doxepin HCl 54 Ereska 54 multicenter randomized placebo controlled 54 immunosuppressant therapies 54 ZYBRESTAT fosbretabulin 54 Bystolic nebivolol 54 Phase III randomized controlled 54 basal insulins 54 imexon 54 oral salmon calcitonin 54 vitro dissolution 54 assessing T DM1 54 COSTAR II 54 highly selective inhibitor 54 CRD5 54 Qnexa TM 54 LibiGel ® testosterone gel 54 taxane resistant 54 INSPIRE Trial Phase III 54 faropenem medoxomil 54 DCVax R 54 ImmunoVEX HSV2 54 Excellarate TM 54 Pafuramidine 54 ARISE Phase III 54 multicenter Phase 54 predictive biomarker 54 pain palliation 54 Oglemilast 54 AFREZZA ® 54 Phase IIa trials 54 Nasdaq ONXX today 54 alkylating agent 54 BrachySil ™ 54 novel immunotherapeutic 54 StemEx 54 trodusquemine 54 initiate Phase IIa 54 unresectable malignant mesothelioma UMM 54 Dyloject TM 54 Phase IIa clinical 54 OVATURE trial 54 Ceplene TM 54 investigational antiplatelet agent 54 fidaxomicin Phase 3 54 SPRYCEL ® 54 thetreatment 54 PLX STROKE targeting 54 immunotherapeutic approaches 54 EndoTAG TM -1 54 thrombin inhibiting aptamer 54 mitoxantrone plus 54 TransVax ™ 54 pharmacodynamic PD 54 Pertuzumab 54 confirmatory Phase III 54 MyVax ® 54 Kinoid 54 opioid bowel dysfunction 54 Tykerb lapatinib 54 EOquin TM 54 ATL# [001] 54 plasma kallikrein inhibitor 54 Perforomist ™ Inhalation Solution 54 CLIRS trial 54 DermaVir Patch 54 nalbuphine ER 53 Hsp# Inhibitor 53 www.heartware.com 53 Nanobody R 53 IIa trial 53 NV1FGF 53 romidepsin novel 53 Inc. OTCBB IRBS 53 multicenter phase 53 refractory gout 53 EC Cysteamine 53 fostamatinib 53 brivaracetam 53 HGS ETR1 mapatumumab 53 CMV vaccine 53 ritonavir boosted danoprevir 53 delta opioid receptor 53 Litx 53 metastatic castration resistant 53 Inc. Nasdaq ALSE 53 PFO migraine 53 BLOOM DM 53 ASG 5ME 53 Presents Preclinical Data 53 GAMMAGARD 53 ENRICH trial 53 regorafenib 53 Nicole Onetto MD 53 Canvaxin 53 confirmatory Phase IIIb 53 mild hepatic impairment 53 randomized controlled Phase 53 collagen vascular 53 HCD# [002] 53 Fibrin Pad 53 Phase IIa trial 53 Excellagen 53 non nucleoside HCV 53 ENDEAVOR IV 53 proprietary intravenous formulation 53 Diamyd ® 53 Phase 2b clinical trials 53 YONDELIS 53 AVN# Phase 53 elotuzumab 53 vosaroxin 53 OMP #M# 53 Tarceva TM 53 Gemzar gemcitabine 53 macitentan 53 Phase #/#a trial 53 motesanib 53 unblinding 53 vinorelbine tartrate 53 TTF Therapy 53 ADAGEN 53 squamous non 53 huN# DM1 53 visiting www.wellpoint.com 53 essential thrombocythemia ET 53 metastatic pancreatic 53 LAB CGRP 53 BR.# 53 Biopharmaceuticals AG 53 Multiple Ascending Dose 53 vaccines oncolytic virus 53 Canvaxin TM 53 Sphingomab TM 53 Xelox 53 Intervention Effectiveness 53 PARTNER Trial 53 VBLOC vagal blocking 53 Randomized controlled 53 ICON7 53 sunitinib malate 53 Phase IIIb 53 controlled multicenter Phase 53 fistulizing Crohn disease 53 TEC #OL 53 WX UK1 53 Vertex hepatitis C 53 Initiate Phase II 53 dose escalation phase 53 Submits Response 53 Pivotal Phase 53 intravenous cyclophosphamide 53 taxane refractory 53 GW# [003] 53 DIRECT Trial 53 SEPET TM 53 hGH CTP Phase 53 edifoligide E2F Decoy 53 Pruvel 53 TOCOSOL R 53 Ketotransdel 53 oral anti arrhythmic 53 thorough QT 53 Provectus Pharmaceuticals specializes 53 OVATURE 53 lintuzumab SGN 53 Acetavance TM intravenous acetaminophen 53 drug GLPG# 53 R vitespen 53 DPX Survivac 53 Solorel 53 ReN# 53 Diamyd r 53 IV RSD# 53 OncoGel 53 Generx TM 53 Deferiprone 53 LBH# 53 Telatinib 53 randomized discontinuation 53 LymphoStat B Phase 53 VitiGam TM 53 cisplatin gemcitabine 53 romidepsin 53 CALGB # [002] 53 fidaxomicin Phase 53 investigational protease inhibitor 53 recurrent glioblastoma 53 BrainGate TM 53 orBec 53 isavuconazole 53 castrate resistant prostate cancer 53 PYY #-# 53 vivo toxicology 53 glucokinase activator 53 Kamada AAT 53 opioid naïve 53 Oncotype DX colon cancer 53 rhThrombin 53 patients receiving myelosuppressive 53 EVIZON ™ 53 Peginterferon alfa 2b 53 forodesine hydrochloride 53 Submits IND 53 successfully commercialize Iluvien 53 Apoptone 53 recurrent malignant glioma 53 Anti VEGF 53 PPAR gamma agonist 53 Harry Palmin President 53 Dr. Adnan Kastrati 53 AcryMed technologies 53 oral rivaroxaban 53 Active Ulcerative Colitis 53 AMPAKINE CX# 53 plus prednisone prednisolone 53 intranasal delivery 53 RhuDex 53 PI3K inhibition 53 PEG PAL 53 anti arrhythmic 53 landmark ATHENA 53 rEV# 53 Phase III LibiGel 53 PRESEPT study 53 MVax 53 Vicriviroc 53 OXi# 53 bardoxolone methyl 53 Arsenic trioxide 53 Phase Ia 53 ChronVac C 53 ACTIVE W 53 systemic RNAi therapeutic 53 Phase 2b randomized 53 angiotensin analog 53 PI3K Akt 53 Phase IIb REGENESIS 53 modified REGENESIS Phase IIb 53 albiglutide currently 53 Wellstat 53 AEG# 53 chemokine receptor 53 alpha antagonist 53 Pharmacokinetic studies 53 Cysview 53 ENDEAVOR III 53 placebo controlled randomized 53 malignant ascites 53 AeroLEF TM 53 Prestara 53 Certolizumab pegol 53 DDP# 53 trastuzumab Herceptin ® 53 ADVANCE PD 53 Tramiprosate ALZHEMED TM 53 kinase inhibition 53 neuropathic pain spasticity 52 LibiGel testosterone gel 52 keloid scarring 52 Maxy G# 52 selectively inhibits 52 SNS# T 52 TACI Ig 52 dacetuzumab 52 induced macular edema 52 optimal dosing regimens 52 metastatic renal cell 52 AVOREN 52 ACCLAIM II 52 subcutaneous ORENCIA 52 cangrelor 52 GLP1 agonist 52 registrational 52 bone marrow reticulin deposition 52 Phase 2a clinical 52 avian influenza viral infections 52 PORxin TM platforms 52 Angiotensin Therapeutic Vaccine 52 telomerase inhibition 52 dirucotide MBP# 52 Arranon 52 Phase 1b 52 REGENESIS Phase IIb 52 Asentar 52 ThermoDox R 52 Vorapaxar 52 Diabetic Macular Edema DME 52 CCR5 antagonist 52 viral protease 52 HuLuc# 52 DU #b 52 Phase #/#a 52 #beta HSD1 52 anti angiogenic agents 52 dose escalation Phase 52 specified primary endpoint 52 IIa trials 52 Exelixis XL# 52 aleglitazar 52 Fibrillex TM 52 HuCNS SC ® 52 Mark A. Sirgo 52 Enhanze Technology 52 Randomized Double blind 52 Amgen Neulasta ® 52 intranasal insulin 52 OLpur TM H2H 52 confirmatory Phase 3 52 familial hypercholesterolemia FH 52 Phase III ThermoDox 52 BN# [002] 52 ropinirole Requip 52 OncoVEX 52 Anturol TM 52 Bevasiranib 52 ancrod 52 trastuzumab DM1 52 MDS AML 52 non hodgkin lymphoma 52 molecular imaging radiopharmaceuticals 52 levodopa induced 52 Telintra 52 cMET 52 selectively inhibited 52 multicenter dose escalation 52 REG2 52 tarenflurbil 52 fallopian tube cancers 52 balsalazide tablet 52 inhaled iloprost 52 registrational trial 52 phase 2a 52 denileukin diftitox 52 castration resistant hormone refractory 52 Immunotherapeutic 52 #I TM# 52 Bioral Amphotericin B 52 indiplon capsules 52 MET inhibitor 52 Amoxicillin PULSYS Phase III 52 malignant mesothelioma Alfacell 52 Ceflatonin R 52 oral taxane 52 Aryplase 52 Maximum Tolerated Dose MTD 52 SCIB1 52 factor TNF receptor 52 CLARITY study 52 Annexin V 52 Preclinical Study 52 CCR1 52 Onyx Pharmaceuticals Announces 52 Gentamicin Surgical Implant 52 acetonide FA 52 Pagoclone 52 SNT MC# 52 systemic ALCL 52 mGluR5 antagonists 52 GetGoal Phase III 52 Clinicaltrials.gov 52 Severe Sepsis 52 LEVADEX ™